Issue link: http://digitaleditions.uberflip.com/i/1535709
NMH | 2024 251 Appendices rates in Ireland following the establishment of a National Gestational Trophoblastic Disease Registry. J Clin Pathol. 2024 Aug 2:jcp-2023- 209270. doi: 10.1136/jcp-2023-209270. Epub ahead of print. PMID: 38555103. Angelini G, Panunzi S, Pompili M, Riccardi L, Garcovich M, Verrastro O, Russo S, Mare T, Luxton J, le Roux CW, Raffaelli M, Mingrone G, Vincent RP. Performance of Noninvasive Tests for Metabolic Dysfunction-Associated Steatohepatitis and Liver Fibrosis Resolution after Bariatric Surgery. Clin Chem. 2024 Dec 30:hvae208. doi: 10.1093/clinchem/hvae208. PMID: 39786442 Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U, Qadri SF, Caiazzo R, Verkindt H, Saponaro C, Kerr-Conte J, Baud G, Marciniak C, Chetboun M, Oukhouya-Daoud N, Blanck S, Vandel J, Olsson L, Chakaroun R, Gnemmi V, Leteurtre E, Lefebvre P, Haas JT, Yki-Järvinen H, Francque S, Staels B, Le Roux CW, Tremaroli V, Mathurin P, Marot G, Romeo S, Pattou F. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024 Dec 9. doi: 10.1038/ s41591-024-03283-1. Online ahead of print. PMID: 39653777 Cohen RV, Park JY, Prager G, Bueter M, le Roux CW, Parmar C, Kermansaravi M, Salminen P, Miras AD. Role of obesity-management medications before and after metabolic bariatric surgery: a systematic review. Br J Surg. 2024 Nov 27;111(12):znae284. doi: 10.1093/bjs/ znae284. PMID: 39612581 Cohen RV, Busetto L, Levinson R, Le Roux CW, Salminen P, Prager G; International Consensus on the Role of Obesity Management Medications in the Context of Metabolic Bariatric Surgery. International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Br J Surg. 2024 Nov 27;111(12):znae283. doi: 10.1093/bjs/znae283. PMID: 39612579 No abstract available. Kosiborod MN, Platz E, Wharton S, le Roux CW, Brueckmann M, Ajaz Hussain S, Unseld A, Startseva E, Kaplan LM; SYNCHRONIZE– CVOT Trial Committees and Investigators. Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC Heart Fail. 2024 Dec;12(12):2101-2109. doi: 10.1016/j. jchf.2024.09.004. Epub 2024 Oct 23. PMID: 39453356 Free article. Review. Coral DE, Smit F, Farzaneh A, Gieswinkel A, Tajes JF, Sparsø T, Delfin C, Bauvin P, Wang K, Temprosa M, De Cock D, Blanch J, Fernández- Real JM, Ramos R, Ikram MK, Gomez MF, Kavousi M, Panova-Noeva M, Wild PS, van der Kallen C, Adriaens M, van Greevenbroek M, Arts I, Le Roux C, Ahmadizar F, Frayling TM, Giordano GN, Pearson ER, Franks PW. Subclassification of obesity for precision prediction of cardiometabolic diseases. Nat Med. 2024 Oct 24. doi: 10.1038/s41591-024-03299-7. Online ahead of print. PMID: 39448862 Cohen RV, Azevedo MA, Le Roux CW, Caldeon LP, Luque A, Fayad DA, Petry TBZ. Metabolic/ Bariatric Surgery is Safe and Effective in People with Obesity, Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Obes Surg. 2024 Nov;34(11):4097-4105. doi: 10.1007/s11695-024-07535-4. Epub 2024 Oct 17. PMID: 39417958 Al Ozairi E, Steenackers N, Pazmino S, Alattar AT, Al Kandari J, Almeda-Valdes P, Antonio-Villa NE, Delfin C, Faradji RN, García-Tuomola A A, Irshad M, Longenecker JC, Rosen J, Hurtado Del Pozo C, Sparsø T, Lavens A, Mathieu C, Van der Schueren B, le Roux CW. Prevalence of obesity in people with and without type 1 diabetes across Belgium, Kuwait, and Mexico: an IMI2 SOPHIA study. EClinicalMedicine. 2024 Oct 3;77:102869. doi: 10.1016/j. eclinm.2024.102869. eCollection 2024 Nov. Ehlers LH, Reinstrup NW, Olesen RH, Holm JC, McEwan P, Le Roux CW. Global barriers to decision makers for prioritizing interventions for obesity. Int J Obes (Lond). 2024 Oct 16. doi: 10.1038/s41366-024-01650-z. PMID: 39414950 Review. le Roux CW, Steen O, Lucas KJ, Ekinci EI, Startseva E, Unseld A, Hussain SA, Hennige AM. Survodutide, a glucagon receptor/ glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial. Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16052. Online ahead of print. PMID: 39582349 No abstract available. Tirzepatide for Obesity Treatment and Diabetes Prevention. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819. Online ahead of print. PMID: 39536238 Contreras F, Al-Najim W, le Roux CW. Health Benefits Beyond the Scale: The Role of Diet and Nutrition During Weight Loss Programmes. Nutrients. 2024 Oct 22;16(21):3585. doi: 10.3390/nu16213585. PMID: 39519418 Free PMC article. Review. Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, Ajaz Hussain S, Pedersen SD, Borowska L, Unseld A, Kloer IM, Kaplan LM; SYNCHRONIZE1 and 2 trial committees and investigators. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Obesity (Silver Spring). 2024 Nov 4. doi: 10.1002/oby.24184. Online ahead of print. PMID: 39495965 Kueh MTW, Chong MC, Miras AD, le Roux CW. Oxyntomodulin physiology and its therapeutic development in obesity and associated complications. J Physiol. 2024 Nov 4. doi: 10.1113/JP287407. Online ahead of print. PMID: 39495024 Review. Le Roux CW, Koroleva A, Larsen S, Foot E. Anti- obesity treatment preferences of healthcare providers and people living with obesity: A survey-based study. Clin Obes. 2024 Oct 28:e12704. doi: 10.1111/cob.12704. Online ahead of print. PMID: 39468412